DE69942307D1 - N-terminal veränderte glp-1 abkömmlinge - Google Patents

N-terminal veränderte glp-1 abkömmlinge

Info

Publication number
DE69942307D1
DE69942307D1 DE69942307T DE69942307T DE69942307D1 DE 69942307 D1 DE69942307 D1 DE 69942307D1 DE 69942307 T DE69942307 T DE 69942307T DE 69942307 T DE69942307 T DE 69942307T DE 69942307 D1 DE69942307 D1 DE 69942307D1
Authority
DE
Germany
Prior art keywords
glp
derivatives
abömmlinge
insulin dependent
terminal changed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942307T
Other languages
English (en)
Inventor
Liselotte Bjerre Knudsen
Per Olaf Huusfeldt
Per Franklin Nielsen
Kjeld Madsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE69942307D1 publication Critical patent/DE69942307D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
DE69942307T 1998-02-27 1999-02-25 N-terminal veränderte glp-1 abkömmlinge Expired - Lifetime DE69942307D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK26898 1998-02-27
DK26398 1998-02-27
DK50898 1998-04-08
PCT/DK1999/000085 WO1999043707A1 (en) 1998-02-27 1999-02-25 N-terminally modified glp-1 derivatives

Publications (1)

Publication Number Publication Date
DE69942307D1 true DE69942307D1 (de) 2010-06-10

Family

ID=27220551

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69942307T Expired - Lifetime DE69942307D1 (de) 1998-02-27 1999-02-25 N-terminal veränderte glp-1 abkömmlinge

Country Status (6)

Country Link
EP (1) EP1062240B1 (de)
JP (1) JP2002506792A (de)
AT (1) ATE466028T1 (de)
AU (1) AU2610899A (de)
DE (1) DE69942307D1 (de)
WO (1) WO1999043707A1 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1932535A3 (de) 1998-07-31 2008-10-29 Novo Nordisk A/S Anregung der Beta-Zellbildung
EP1076066A1 (de) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptide zur Senkung des Blutglukosespiegels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1634605A3 (de) 2000-03-08 2006-10-11 Novo Nordisk A/S Behandlung von Dyslipämie bei einem Patienten mit Typ 2 Diabetes
KR20030009389A (ko) * 2000-03-14 2003-01-29 브루카드 괴케 유문동-유문-십이지장 운동성에 대한 글루카곤 유사펩티드-1 (7-36)의 효과
JP2004509079A (ja) * 2000-08-02 2004-03-25 セラテクノロジーズ・インコーポレーテッド 効力が増大した修飾生体ペプチド
EP1346722B1 (de) 2000-12-01 2008-12-10 Takeda Pharmaceutical Company Limited Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
CA2434237C (en) * 2000-12-07 2012-05-15 Eli Lilly And Company Glp-1 fusion proteins
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
MXPA04001525A (es) * 2001-08-23 2004-05-31 Lilly Co Eli Analogos de peptido -1 similar al glucagon.
EP1432430A4 (de) * 2001-08-28 2006-05-10 Lilly Co Eli Vormischungen von glp-1 und basalinsulin
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
DE60230818D1 (de) 2001-09-24 2009-02-26 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
JP2005508360A (ja) * 2001-10-19 2005-03-31 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１およびインスリンの二相混合物
CA2468700A1 (en) 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
JP2006501820A (ja) * 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
AU2003271452A1 (en) 2002-09-25 2004-04-19 Theratechnologies Inc. Modified glp-1 peptides with increased biological potency
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
WO2004067548A2 (en) * 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
EP1626981A4 (de) * 2003-03-04 2006-11-22 Biorexis Pharmaceutical Corp Dipeptidylpeptidase-geschützte proteine
CN102174102A (zh) 2003-05-15 2011-09-07 塔夫茨大学信托人 肽和多肽药物的稳定类似物
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
ES2380437T3 (es) 2003-06-03 2012-05-11 Novo Nordisk A/S Composiciones farmacéuticas de péptido GLP-1 estabilizadas
CA2539253A1 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CN100444898C (zh) * 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
EP1667724A2 (de) * 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin bindende derivate von therapeutischen peptiden
MXPA06005581A (es) 2003-11-20 2006-08-11 Novo Nordisk As Formulaciones de peptidos que contienen propilenglicol que son optimas para la produccion y uso en dispositivos de inyeccion.
JP4865565B2 (ja) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
EP2210900A3 (de) * 2003-12-16 2010-08-11 Ipsen Pharma GlLP-1-Analoga
EP1758575A1 (de) 2004-06-11 2007-03-07 Novo Nordisk A/S Bekämpfung von arzneimittel-induzierter fettleibigkeit unter verwendung von glp-1-agonisten
ES2442223T3 (es) 2004-08-31 2014-02-10 Novo Nordisk A/S Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas
WO2006051110A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of insulinoptropic peptides
KR20070120112A (ko) 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 ｇｌｐ-1 화합물
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
JP2008539735A (ja) * 2005-05-06 2008-11-20 バイエル・フアーマシユーチカルズ・コーポレーシヨン グルカゴン様ペプチド１（ｇｌｐ−１）受容体アンタゴニストおよびそれらの薬理学的使用方法
WO2007075534A2 (en) * 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
CA2658654A1 (en) 2006-07-24 2008-01-31 Biorexis Pharmaceutical Corporation Exendin fusion proteins
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
KR20110122100A (ko) 2009-01-22 2011-11-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 안정한 성장 호르몬 화합물
EP2461831B1 (de) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Wachstumshormone mit verlängerter in-vivo-wirksamkeit
DK2513140T3 (en) * 2009-12-16 2016-01-18 Novo Nordisk As Double-acylated GLP-1 derivatives
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
CN102834109B (zh) 2010-01-22 2016-01-20 诺沃—诺迪斯克保健股份有限公司 稳定的生长激素化合物
EP2555791B1 (de) 2010-04-09 2017-11-01 Sinai Health System Verfahren zur behandlung von erkrankungen des magen-darm-trakts mittels eines glp-1-agonisten
SG184988A1 (en) 2010-04-27 2012-11-29 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
KR20130093470A (ko) 2010-04-30 2013-08-22 가부시키가이샤산와카가쿠켄큐쇼 생리활성 물질 등의 생체 내 안정성 향상을 위한 펩티드 및 생체 내 안정성이 향상된 생리활성 물질
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
DK3326620T3 (da) 2010-12-16 2020-05-25 Novo Nordisk As Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre
MX355361B (es) 2011-04-12 2018-04-17 Novo Nordisk As Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
BR112014010780A2 (pt) 2011-11-03 2017-04-25 Zealand Pharma As conjugados do peptídeo agonista do receptor glp-1-gastrina
AU2013234496B2 (en) 2012-03-22 2017-07-27 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
EP4331667A2 (de) 2012-03-22 2024-03-06 Novo Nordisk A/S Zusammensetzungen mit einem abgabemittel und herstellung davon
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
NZ704043A (en) 2012-07-23 2017-07-28 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US20150273069A1 (en) 2012-10-17 2015-10-01 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
JP6464145B2 (ja) 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物製剤
PL3057984T3 (pl) 2013-10-17 2018-12-31 Zealand Pharma A/S Acylowane analogi glukagonu
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
MX369770B (es) 2013-11-06 2019-11-21 Zealand Pharma As Compuestos agonistas triples de glucagón-glp-1-gip.
EP3065767B1 (de) 2013-11-06 2020-12-30 Zealand Pharma A/S Zweifach-gip-glp-1-agonistenverbindung und verfahren
EP3006045B3 (de) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmazeutische Formulierungen zur oralen Verabreichung von Peptid- oder Proteinarzneimitteln
CA2965732A1 (en) 2014-10-29 2016-05-06 Zealand Pharma A/S Gip agonist compounds and methods
JP6989385B2 (ja) 2015-04-16 2022-01-05 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
CA2997343A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
JP6563614B1 (ja) 2016-12-09 2019-08-21 ジーランド・ファーマ・ア／エス アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
TWI783890B (zh) 2017-08-24 2022-11-11 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
IL275778B2 (en) 2018-02-02 2023-12-01 Novo Nordisk As Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt
BR112020019148A2 (pt) * 2018-03-23 2021-01-26 Carmot Therapeutics, Inc. moduladores de receptores acoplados à proteína g
KR20200141469A (ko) 2018-04-05 2020-12-18 썬 파마슈티칼 인더스트리스 리미티드 신규한 glp-1 유사체
US20210087250A1 (en) 2018-04-06 2021-03-25 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
KR20220143037A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 Glp-1 조성물 및 이의 용도
JP2023524695A (ja) 2020-04-29 2023-06-13 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬およびヒスチジンを含む固形組成物
CN116419750A (zh) 2020-09-07 2023-07-11 西普鲁梅有限公司 改进的glp-1受体激动剂的药物制剂
KR20230083294A (ko) 2020-09-30 2023-06-09 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩타이드 접합체 및 사용 방법
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341320C (en) 1986-05-05 2001-11-20 Joel Habener Insulinotropic hormone
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
ATE193541T1 (de) 1989-03-20 2000-06-15 Gen Hospital Corp Insulinotropes hormon
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5869602A (en) * 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
CZ297338B6 (cs) * 1996-03-01 2006-11-15 Novo Nordisk A/S Peptid potlacující chut k jídlu, farmaceutický prostredek jej obsahující a jeho pouzití
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate

Also Published As

Publication number Publication date
AU2610899A (en) 1999-09-15
EP1062240B1 (de) 2010-04-28
ATE466028T1 (de) 2010-05-15
JP2002506792A (ja) 2002-03-05
EP1062240A1 (de) 2000-12-27
WO1999043707A1 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
DE69942307D1 (de) N-terminal veränderte glp-1 abkömmlinge
WO1999043705A8 (en) N-terminally truncated glp-1 derivatives
DE68929217D1 (en) Insulinotropes hormon
Adelhorst et al. Structure-activity studies of glucagon-like peptide-1.
PH12021550154A1 (en) Gip/glp1 co-agonist compounds.
WO2006121860A3 (en) Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
NO992557L (no) Bruk av GLP-1-analoger og derivater administrert perifert i regulering av fedme
DE69327309T2 (de) Verwendung eines peptids
PE47096A1 (es) Analogo, composicion y uso del peptido insulinotropico similar al glucagon
DK0699686T3 (da) Biologisk aktive fragmenter af glukagon-lignende insulinotropisk peptid
EP2070946A3 (de) Erfindung betreffend GLP-1 und Exendin
EA199900169A1 (ru) Применение глюкагоноподобного пептида-1 (glp-1) или его аналогов для устранения катаболических изменений после оперативного вмешательства
NO20063436L (no) Intranasal administrasjon av glukose-regulerende peptider
BR0116024A (pt) Proteìna de fusão heteróloga e uso da mesma
EA200100289A1 (ru) Способ введения инсулинотропных пептидов
BR9607647A (pt) Derivado de insulina e composição farmacêutica e processo para o tratamento de diabetes em um paciente em necessidade deste tratamento
WO2003082898A2 (en) Novel analogues of glucose-dependent insulinotropic polypeptide
JP2004509079A5 (de)
DE60110054D1 (en) Cardioprotektive phosphonate
MX2022009149A (es) Compuestos coagonistas de gip/glp1.
TW200716156A (en) Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonists and their pharmacological methods of use
Kühn-Wache et al. Analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance
Hinke et al. Structure-activity relationships of glucose-dependent insulinotropic polypeptide (GIP)
PE108199A1 (es) Composicion farmaceutica de tiazolidindiona y sulfonilurea
Hinke et al. [Ser2]-and [Ser (p) 2] incretin analogs: Comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo

Legal Events

Date Code Title Description
8364 No opposition during term of opposition